RenaissThera Advances Oral Drug Development for Obesity and Type 2 Diabetes

Biotechnology

30 July 2026 at 7:30 pm

RenaissThera Advances Oral Drug Development for Obesity and Type 2 Diabetes

HyperFast News

Summary

RenaissThera, a Bengaluru-based company founded in 2023, is developing oral small-molecule drugs for obesity and type 2 diabetes, focusing on targets like GLP-1 and GIP. The company has raised seed funding and is using AI and machine learning in its drug discovery process, with seven programs currently at the discovery stage.

Select what you want to create

Turn this story into an image post, carousel, video, audio reel, blog, and more — all from HyperFast News.

FAQ

Newsroom FAQs

About the public HyperFast News news feed powered by NewsEngine.

RenaissThera Advances Oral Drug Development for Obesity and Type 2 Diabetes | HyperFast News